MSI status has significant clinical implications. Patients with MSI-H tumors generally have a better prognosis compared to those with microsatellite stable (MSS) tumors. Moreover, MSI status is a crucial factor in determining treatment strategies, particularly the use of immunotherapy agents like PD-1 inhibitors.
